Eventide Asset Management, LLC Zentalis Pharmaceuticals, Inc. Transaction History

Eventide Asset Management, LLC

$5.22 Billion
Q4 2024

A detailed history of Eventide Asset Management, LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Eventide Asset Management, LLC holds 4,475,054 shares of ZNTL stock, worth $10.4 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares

4,475,054

Previous 8,547,896 47.65%

Holding current value

$10.4 Million

Previous $31.4 Million 56.78%

% of portfolio

0.26%

Previous 0.55%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$2.7 - $4.03 $11 Million - $16.4 Million	-4,072,842 Reduced 47.65%	4,475,054 $13.6 Million
Q2 2024 Aug 13, 2024	SELL	$4.09 - $16.13 $12.4 Million - $48.8 Million	-3,026,925 Reduced 26.15%	8,547,896 $35 Million
Q1 2024 May 15, 2024	BUY	$10.83 - $16.49 $160,782 - $244,810	14,846 Added 0.13%	11,574,821 $182 Million
Q4 2023 Feb 14, 2024	BUY	$9.84 - $20.13 $36.9 Million - $75.4 Million	3,745,936 Added 47.94%	11,559,975 $175 Million
Q3 2023 Nov 14, 2023	BUY	$19.63 - $28.29 $18.4 Million - $26.5 Million	936,236 Added 13.61%	7,814,039 $157 Million
Q2 2023 Aug 15, 2023	BUY	$17.41 - $30.05 $63.6 Million - $110 Million	3,650,803 Added 113.13%	6,877,803 $194 Million
Q1 2023 May 15, 2023	BUY	$16.14 - $24.94 $17.3 Million - $26.7 Million	1,070,485 Added 49.64%	3,227,000 $55.5 Million
Q4 2022 Feb 13, 2023	BUY	$18.07 - $25.6 $5.34 Million - $7.57 Million	295,515 Added 15.88%	2,156,515 $43.4 Million
Q3 2022 Nov 14, 2022	BUY	$20.23 - $31.73 $17.3 Million - $27.2 Million	857,000 Added 85.36%	1,861,000 $40.3 Million
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $4.35 Million - $12.7 Million	243,000 Added 31.93%	1,004,000 $28.2 Million
Q1 2022 May 16, 2022	BUY	$41.58 - $80.89 $9.65 Million - $18.8 Million	232,000 Added 43.86%	761,000 $35.1 Million
Q3 2021 Nov 15, 2021	BUY	$46.83 - $73.5 $5.09 Million - $7.98 Million	108,600 Added 25.83%	529,000 $35.3 Million
Q2 2021 Aug 16, 2021	SELL	$37.41 - $62.25 $15.4 Million - $25.6 Million	-411,600 Reduced 49.47%	420,400 $22.4 Million
Q4 2020 Feb 16, 2021	SELL	$31.71 - $57.97 $2.52 Million - $4.6 Million	-79,416 Reduced 8.71%	832,000 $43.2 Million
Q3 2020 Nov 13, 2020	SELL	$27.03 - $47.97 $88,901 - $157,773	-3,289 Reduced 0.36%	911,416 $28.8 Million
Q2 2020 Aug 14, 2020	BUY	$23.2 - $54.8 $21.2 Million - $50.1 Million	914,705 New	914,705 $42.5 Million

Others Institutions Holding ZNTL

# of Institutions

147

Shares Held

65.3M

Call Options Held

43.2K

Put Options Held

21.7K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $132M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eventide Asset Management, LLC with notifications on news.

Account

Eventide Asset Management, LLC Zentalis Pharmaceuticals, Inc. Transaction History